Seropeutics

Category
Spinouts
About This Project

Problem

Infants diagnosed with Fragile X syndrome face a future marked by cognitive decline, speech impairment, heightened anxiety, hyperactivity, irritability, and impulsivity. Current treatments are piecemeal and riddled with side effects.

Solution

Seropeuticsdevelops efficacious therapies addressing the needs of Fragile X syndrome, and has identified two promising candidates, SERx – 519 and SERx – 480, that ameliorate core symptoms while measurably reducing side effects.

Leadership

Executive Chairman & CEO

Donald Kiepert

Scientific Founder and Chief Scientist

Raymond Booth

For more information about Seropeutics, contact Donald Kiepert.